Balinatunfib - Sanofi
Alternative Names: SAR-441566Latest Information Update: 05 Nov 2026
At a glance
- Originator Sanofi
- Class Amines; Anti-inflammatories; Antipsoriatics; Antirheumatics; Azabicyclo compounds; Benzimidazoles; Cyclobutanes; Fluorinated hydrocarbons; Heterocyclic compounds with 4 or more rings; Ketones; Phenyl ethers; Pyrimidines; Small molecules
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Crohn's disease; Inflammation; Psoriasis; Rheumatoid arthritis; Ulcerative colitis
Most Recent Events
- 22 Oct 2026 Sanofi terminates phase II trials in Crohn's disease and Ulcerative colitis (Treatment-experienced) in Chile, Bulgaria, China, Czech Republic, Argentina, Italy, USA, due to business decision (PO) (NCT07222189)
- 02 Oct 2026 Sanofi terminates phase II trial in Crohn's-disease in Australia, Turkey, Spain, South Korea, Romania, Poland, Netherlands, Mauritius, Japan, Italy, India, Hungary, Germany, Georgia, France, Czech Republic, Croatia, China, Chile, Canada, Bulgaria, Brazil, Arentina and the USA (NCT06637631)
- 30 Jul 2026 Discontinued - Phase-II for Crohn's disease (Treatment-experienced) in Argentina, Brazil, Canada, China, Croatia, Czech Republic, Georgia, France, Germany, Hungary, India, Italy, Japan, Mauritius, Netherlands, Poland, Romania, South Korea, Spain, Turkey (PO)